Rheumatologist, enthusiastic photography, astronomy and psychology.
Joined March 2009
- Tweets1.4K
- Following193
- Followers455
- Likes3.8K
Pinned Tweet
🧲🤩 Thrilled to share our new @eular_org #classification criteria for #HaemochromatosisArthropathy! A long-overlooked, iron-driven arthritis finally gets the attention it deserves.
Proud to have contributed to this international effort.
See 👉🏼POS0558
#EULAR2025 #rheumatology
At #EULAR2026 we presented our work OP071 on synovial biopsy–driven therapeutic stratification in #PsoriaticArthritis.
Our preliminary data suggest that CD117+ myeloid synovitis may support IL-17/IL-23 axis targeting in selected PsA patients.
#PsA #Rheumatology #PrecisionMedicine
🤖 Made with AI
🚀4th edition of #Reumasport has just concluded
Challenging the paradigm: patients with rheumatic diseases are not fragile → they are trainable💪
🔥Multidisciplinary approach, exercise as therapy,real-world vision
🚀 #ReumasportStudyGroup is now launched
IG: @reumasport_official
35
🤔Does prior IL-17i exposure affect retention in PsA?
🌍Real-world data from the BIRRA Study Group (868 patients across 24 centres) suggest no major impact.
💡Evidence supporting IL-17i cycling in selected patients.
🔗 link.springer.com/epdf/10.10…
#PsoriaticArthritis #Rheumatology
1
62
🎙️ New podcast by EMEUNET
With Patrick Kiely, we discuss haemochromatosis arthropathy
🔎 When to suspect it
🦴 Key clinical & radiographic clues
💡 Practical take-home messages
🎧 urly.it/31d-n5
#Rheumatology #Haemochromatosis #EULAR #MedicalEducation
3
53
🎉EULAR 2025 Classification Criteria for Haemochromatosis Arthropathy
📘 Ann Rheum Dis 👉 ard.eular.org/article/S0003-…
Proud to be part of this international effort led by Patrick Kiely with amazing colleagues, @EULAR_org & patient partners.
Thanks to @EMEUNET for the opportunity! 💪
🧩 New publication “Guselkumab effectiveness in real-world settings: Italian multicentre study”
🔗 doi.org/10.1093/rap/rkaf094
📌26 Italian rheumatology centers (BIRRA network)
📊 278 PsA patients
#PsoriaticArthritis #Rheumatology #RealWorldEvidence #IL23 #Guselkumab #BIRRAstudy
1
121
🔎 #Ultrasound as a diagnostic tool in #PMR
New study @Rheumatol_Int ➡️Bilateral subacromial-subdeltoid bursitis > 3 mm can reliably distinguish Polymyalgia Rheumatica from rotator cuff tendinopathy.
📊 Specificity: 96.3%
📊 Sensitivity: 84.2%
👉urly.it/31c08f
🧐Granulomatosis with polyangiitis #GPA can present as a diagnostic emergency.A multidisciplinary approach led to timely treatment despite no initial biopsy. Later confirmation: necrotizing vasculitis.Teamwork saves lives.😎
👉🏼urly.it/31b8f2 👀
#vasculitis #rheumatology
1
126
A landmark moment at #EULAR2025
🏛️ Patrick Kiely presented the EULAR Classification Criteria for Haemochromatosis Arthropathy (HA) — the first-ever criteria for this long-neglected yet disabling condition.
#Haemochromatosis #Arthropathy #EULAR2025 #ClassificationCriteria
📢Don’t miss the presentation of the brand-new EULAR Classification Criteria for Haemochromatosis Arthropathy!
🗓️June 14,09:45–10:00
📍Room D1 | Session: EULAR Recommendations II
🎙️Speaker:Patrick Kiely
#EULAR2025 #Rheumatology #Haemochromatosis #Arthropathy #EULARRecommendations
3
177
🔵Poster POS0334 | #EULAR2025
Colchicine still matters in mucosal #Behçet:
📈Withdrawal led to significant ↑ in oral ulcers at 12 weeks (2.7 vs 0.9; p<0.001)
🔹Higher relapse in women
🔹Also impact on other mucocutaneous lesions.
#BehçetSyndrome #Vasculitis #Colchicine
🟣 Poster POS0333 | #EULAR2025
Apremilast shows efficacy in refractory mucosal #Behçet’s syndrome:
🔹93.5% OU response
🔹↓ Ulcer scores
🔹Transcriptomics: downreg of interferon & monocyte pathways
📉Relapse rate still ~43%, but molecular data suggest targeted immune modulation.
8
423
🧠🫀From EGPA to GCA and ANCA-AAV: exciting insights from poster tours at #EULAR2025!
🧪GC-sparing, PET/CT radiomics,avacopan, OCT biomarkers & MMP-3 for PMR-mimics,vasculitis research is evolving fast.
🔍Science meets clinical relevance!
#Vasculitis #Rheumatology #EGPA #GCA #AAV
4
347
💪 Finally! At #EULAR2025, a whole session dedicated to the role of sport in RMDs 🙌
From evidence to practice, from inflammation control to pain relief, sport is medicine.
🧠 “A DMARD and a painkiller”? Yes, with data to back it.
#RheumTwitter #ExerciseIsMedicine #RMDs
🌿 An inspiring & high-impact session on #SystemicSclerosis at #EULAR2025!
From vasodilators & PAH therapy to gene modulation and CAR-T for drug-free responses.
Here’s a thread with the highlights 👇
#SSc #Vasculopathy #RheumTwitter
📸Continuing the “not just science” series😜
Colleagues @docGmG and Dott Bardelli— the fun ones, the kind you truly enjoy working with (and hanging out with).Because a congress is also about real connections, spontaneous laughs,and good vibes all around.
#EULAR2025 #RheumFriends
5
186
🔍 Highlights from the #EULAR2025 myositis session — cutting-edge work by Chifumi Akiyama & Michael Bubb.
From cluster phenotyping in ASS-ILD to stem cell therapy in refractory myopathies.
👇🧵
#Myositis #Autoimmunity
– Michael Bubb
🌱 OP0318 | Phase 1 trial on umbilical cord lining stem cells (ULSC) in idiopathic inflammatory myopathies
→ Dose-escalation design (50–200M ULSC)
→ Target: reduce steroids + improve TIS
→ Novel immune modulation approach
#Myositis #StemCells #EULAR2025
1
1
83
🔥 POS1124 | A major step for #VEXAS: an international expert panel reached consensus on the definition of a VEXAS flare using Delphi methodology.
➡️3 categories, adjudication pathway, and a clear criterion: GC escalation.
Crucial for trials, therapy, and patient care.
#EULAR2025
POS0325 at #EULAR20205
🤩Super-responders to RTX exist!
3 years remission after a single cycle
✅➡️Predictors: APS, longer disease duration
→ May guide future CD20 or CAR-T strategies
@LeedsMedHealth
@Yuz6Yusof
